Larimar Therapeutics, Inc. (LRMR): Price and Financial Metrics
GET POWR RATINGS... FREE!
LRMR Stock Price Chart Interactive Chart >
LRMR Price/Volume Stats
| Current price | $4.67 | 52-week high | $10.05 |
| Prev. close | $4.20 | 52-week low | $1.53 |
| Day low | $4.25 | Volume | 58,800 |
| Day high | $4.78 | Avg. volume | 52,111 |
| 50-day MA | $3.96 | Dividend yield | N/A |
| 200-day MA | $3.05 | Market Cap | 82.71M |
Larimar Therapeutics, Inc. (LRMR) Company Bio
Larimar Therapeutics, Inc. operates as a biotech company. The Company develops and discovers treatments for complex rare diseases such as protein replacement therapy. Larimar Therapeutics serves customers in the State of Pennsylvania.
Latest LRMR News From Around the Web
Below are the latest news stories about LARIMAR THERAPEUTICS INC that investors may wish to consider to help them evaluate LRMR as an investment opportunity.
Larimar Therapeutics to Present at the 34th Annual Piper Sandler Healthcare ConferenceBALA CYNWYD, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will present and participate in 1x1 investor meetings at the 34th Annual Piper Sandler Healthcare Conference, which is taking place in New York, NY from November 29 – December 1, 2022. The Company’s presentation will take place on Thursday, December 1, 2 |
Analysts’ Top Healthcare Picks: Larimar Therapeutics (LRMR), SCYNEXIS (SCYX)There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Larimar Therapeutics (LRMR – Research Report) and SCYNEXIS (SCYX – Research Report) with bullish sentiments. Larimar Therapeutics (LRMR) JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Larimar Therapeutics today and set a price target of $16.00. The company's shares closed last Thursday at $3.07, close to its 52-week low of $1.53. According to TipRanks.com, Wolleben is ranked 0 out of 5 stars with an average return of -38.9% and a 14.0% success rate. |
Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial ResultsFirst cohort of Larimar’s Phase 2 dose exploration trial of CTI-1601 in Friedreich’s ataxia patients is ongoing and proceeding in line with the Company’s planned timelineLarimar expects to provide an update on the Phase 2 trial in Q2 2023 and anticipates reporting top-line data from both cohorts in 2H 2023Cash of $124.7 million at September 30, 2022 provides projected cash runway into 2H 2024 BALA CYNWYD, Pa., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR |
Larimar Therapeutics to Participate in the Guggenheim 4th Annual Immunology & Neurology DayBALA CYNWYD, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in a virtual fireside chat and 1x1 investor meetings at the Guggenheim 4th Annual Immunology & Neurology Day, which is taking place from November 14 – 15, 2022. Details on the fireside chat can be found below. Date:Tuesday, November 15, |
Larimar Therapeutics Announces Issuance of U.S. Patent Providing Composition of Matter Protection for CTI-1601Patent extends Larimar’s intellectual property protection for CTI-1601 into at least July 2040 BALA CYNWYD, Pa., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the issuance of U.S. Patent No. 11,459,363. The patent, titled, “Materials and Methods for Treating Friedreich's Ataxia,” provides composition of matter protection for CTI-1601 into a |
LRMR Price Returns
| 1-mo | 13.90% |
| 3-mo | 55.67% |
| 6-mo | 160.89% |
| 1-year | -47.76% |
| 3-year | -65.25% |
| 5-year | -93.37% |
| YTD | 13.08% |
| 2022 | -61.72% |
| 2021 | -49.60% |
| 2020 | 60.74% |
| 2019 | -77.58% |
| 2018 | 7.14% |
Loading social stream, please wait...